[HTML][HTML] A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts

BB Azad, S Chatterjee, WG Lesniak, A Lisok… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Oncotarget, 2016ncbi.nlm.nih.gov
For physiologically important cancer therapeutic targets, use of non-invasive imaging for
therapeutic guidance and monitoring may improve outcomes for treated patients. The CXC
chemokine receptor 4 (CXCR4) is overexpressed in many cancers including non-small cell
lung cancer (NSCLC) and triple negative breast cancer (TNBC). CXCR4 overexpression
contributes to tumor growth, progression and metastasis. There are several CXCR4-targeted
therapeutic agents currently in clinical trials. Since CXCR4 is also crucial for normal …
Abstract
For physiologically important cancer therapeutic targets, use of non-invasive imaging for therapeutic guidance and monitoring may improve outcomes for treated patients. The CXC chemokine receptor 4 (CXCR4) is overexpressed in many cancers including non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). CXCR4 overexpression contributes to tumor growth, progression and metastasis. There are several CXCR4-targeted therapeutic agents currently in clinical trials. Since CXCR4 is also crucial for normal biological functions, its prolonged inhibition could lead to unwanted toxicities. While CXCR4-targeted imaging agents and inhibitors have been reported and evaluated independently, there are currently no studies demonstrating CXCR4-targeted imaging for therapeutic guidance.
ncbi.nlm.nih.gov